Position Paper

EBE Position Paper on Tendering of Biologicals, including Biosimilars

21 May 2012

The procurement practice is primarily used for medicines which are genuinely identical, bio-equivalent, multi-sourced and off-patent, i.e., small chemical molecules, so-called generics and their originators that have lost patent and exclusivity. However, the same criteria can not be applied when selecting and purchasing non-identical medicines, notably biologicals, including biosimilars.

Read the position paper here

2017-08-30T13:19:28+00:00May 21, 2012|